Head-to-head evidence
ASC30 vs efsubaglutide alfa
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Obesity
Shared mechanism: GLP-1 receptor · full Obesity pipeline
ASC30
Developed by Ascletis Pharma
NCT07002905 · Phase 2 · completed
The study randomly assigned 125 participants and used quadruple blinding with placebo control across seven cohorts. Its primary endpoint was percent change in body weight at Week 13, but the registry has not posted whether this endpoint was met.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: July 2028 · NCT07743450 (registry estimate)
efsubaglutide alfa
Developed by Shanghai Yinnuo Pharmaceutical Technology
NCT06732960 · Phase 2 · completed
The study was randomized, double-blind, and placebo-controlled, but each dose cohort was small, with approximately 10 participants per cohort and a 8:2 active-to-placebo allocation. Because the registry provides no primary endpoint results, it is not possible to determine whether the weight-loss comparison was met.
Next expected readout: November 2026 · NCT07163650 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ASC30's landscape · efsubaglutide alfa's landscape